Daridorexant’s latest market price and trend analysis in 2025

Daridorexant (Daridorexant) is a new dual orexin receptor antagonist, mainly used to treat insomnia in adults. It helps patients shorten the time it takes to fall asleep and improve sleep quality by regulating the brain's arousal system. It is considered an important breakthrough in the field of insomnia treatment in recent years. In 2025, DaliRasen has been officially launched in China. Although it has not been on the market for a long time, it has quickly attracted widespread attention from clinical and patient groups due to its unique mechanism of action and good safety. However, as it is not yet included in medical insurance, the economic accessibility of drugs is still an important factor affecting their popularity.

At present, although Dali Resonance is on the market in China, it is not yet easy to purchase it on a large scale in the market because supply channels are still being gradually established. In terms of price, domestic pricing has not yet been fully open and transparent, but it is generally believed to be close to or even slightly higher than the international market. Since there is no medical insurance reimbursement policy, patients need to bear the entire cost of the medicine themselves when purchasing it, which is a considerable burden for some insomnia patients who have been taking medicine for a long time. In addition, due to limited production and circulation in the initial stage of marketing, some regions may experience insufficient supply or need to obtain it through formal cross-border drug purchase channels.

In foreign markets, the current price of the European version of DaliRasen's original drug is about more than 2,000 yuan. Since the drug has just come out, there are no generic drugs on the market yet, so the price is still at a high level and patients' choices are relatively limited. Compared with other insomnia drugs, the price of DaliRasen is at the mid-to-high-end level, but its effect in improving sleep quality is more significant, and it is especially suitable for patients who have ineffective or intolerant effects of traditional sedative-hypnotics. Therefore, even though the price is not low, some overseas patients still choose to continue using it.

Judging from the overall trend in 2025, as DaliRaxon gradually expands its sales scale globally, increases production capacity and advances in the research and development of generic drugs, prices are expected to gradually decline in the future. If the drug can be included in China's medical insurance catalog in the next few years, the financial burden on patients will be significantly reduced, and the market penetration rate will also increase rapidly. At the same time, domestic and foreign pharmaceutical companies are accelerating the research and development process of generic drugs and alternative drugs. More versions with more competitive prices may appear in the future, further stabilizing market prices. Overall, the price of Dali Rayson is still in a high range in the short term, but the long-term trend is expected to develop in a more affordable direction.

Reference materials:https://www.drugs.com/